ANI CEO Przybyl To Depart After 11 Years
Comes As Firm Gears Up For Cortrophin Gel Entry
ANI Pharmaceuticals has been steered by former Akorn head Arthur Przybyl since March 2009. But he will bring the curtain down on his time with the company next month, as the company recruits his replacement ahead of a key branded product launch.
You may also be interested in...
US-based ANI Pharmaceuticals has made manufacturing and API changes as part of its refiled package for Cortrophin Gel (corticotropin) for injection, which it hopes will be a “transformational opportunity.”
ANI revealed last month that long-serving company head Arthur Przybyl would be departing after 11 years at the top. The US-based player has just announced its interim chief as it reported first-quarter sales, following the landmark US portfolio acquisition from Amerigen in January, and made a major announcement for its full-year financial guidance.
In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.